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Abstract: Casein kinase 2 (CK2) is a highly ubiquitous and conserved serine/threonine kinase that
forms a tetramer consisting of a catalytic subunit (CK2α) and a regulatory subunit (CK2β). Despite
being ubiquitous, CK2 is commonly found at higher expression levels in cancer cells, where it
inhibits apoptosis, and supports cell migration and proliferation. The Ca2+-activated chloride channel
TMEM16A shows similar effects in cancer cells: TMEM16A increases cell proliferation and migration
and is highly expressed in squamous cell carcinoma of the head and neck (HNSCC) as well as
other malignant tumors. A microscopy-based high-throughput screening was performed to identify
proteins that regulate TMEM16A. Within this screen, CK2 was found to be required for proper
membrane expression of TMEM16A. small interfering (si) RNA-knockdown of CK2 reduced plasma
membrane expression of TMEM16A and inhibited TMEM16A whole cell currents in (cystic fibrosis
bronchial epithelial) CFBE airway epithelial cells and in the head and neck cancer cell lines Cal33
and BHY. Inhibitors of CK2, such as TBB and the preclinical compound CX4549 (silmitasertib), also
blocked membrane expression of TMEM16A and Ca2+-activated whole cell currents. siRNA-knockout
of CK2 and its pharmacological inhibition, as well as knockdown or inhibition of TMEM16A by either
niclosamide or Ani9, attenuated cell proliferation. Simultaneous inhibition of CK2 and TMEM16A
strongly potentiated inhibition of cell proliferation. Although membrane expression of TMEM16A
is reduced by inhibition of CK2, our data suggest that the antiproliferative effects by inhibition of
CK2 are mostly independent of TMEM16A. Simultaneous inhibition of TMEM16A by niclosamide
and inhibition of CK2 by silmitasertib was additive with respect to blocking cell proliferation, while
cytotoxicity was reduced when compared to solely blockade of CK2. Therefore, parallel blockade
TMEM16A by niclosamide may assist with anticancer therapy by silmitasertib.
Keywords: TMEM16A; anoctamin 1; Ca2+ activated Cl− channel; Casein kinase 2; CK2; cancer;
proliferation
1. Introduction
Casein kinase 2 (CK2) is a highly ubiquitous and conserved serine/threonine kinase that
forms a tetramer consisting of a catalytic subunit (CK2α) and regulatory subunit (CK2β) [1]. CK2
phosphorylates hundreds of substrates. It contributes to a large number of cellular processes, but its
main functions are related to cell growth, proliferation, and cell survival [2]. It supports cell proliferation
and survival by antagonizing caspase activity and by potentiating survival signals. A multitude of
mechanisms may contribute to these antiapoptotic functions [3]. A common inhibitor of CK2 that
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has been frequently used in previous studies is 4,5,6,7-tetrabromobenzotriazole (TBB) [4]. The orally
bioavailable selective inhibitor of CK2, CX4945 (silmitasertib), has been shown to be antiproliferative
and anti-angiogenic. It has the potential to be the first oral CK2 inhibitor that may advance from
clinical trials to treatment of cancer patients [5,6].
TMEM16A belongs to a family of Ca2+-activated phospholipid scramblases and ion channels [7,8].
The 10 TMEM16 paralogs (ANO1-10; TMEM16A-K) are broadly expressed in epithelial and
non-epithelial tissues [9]. TMEM16A is a Cl− selective anion channel [10] with well-described
functions in a number of tissues. TMEM16A is upregulated during cellular dedifferentiation and in
cultured cells. It increases proliferation in many different tissues [11–20], and is expressed at high
levels, particularly in head and neck cancers [15,16,21]. We recently identified niclosamide as a potent
inhibitor of TMEM16A [22]. Niclosamide is an anthelminthic drug approved by the U.S. Food and
Drug Administration that was also shown to inhibit Notch signaling [23], a pathway that is well known
to participate in tumorigenesis [24]. A number of antineoplastic mechanisms of niclosamide have been
described. Thus, niclosamide was shown to inhibit nuclear factor kappa B (NF-κB), Wnt/ß-catenin
signaling, the IL-6-JAK1-STAT3-pathway, GSK-3 and more [25–33]. A recent paper suggests cell cycle
arrest by niclosamide through activation of the Let-7d/CDC34 axis [34].
Niclosamide has been used in a number of preclinical studies and even in clinical trials with
patients suffering from prostate and colorectal cancer [28,30,35–39]. Apart from various anti-cancer
effects, niclosamide also inhibits the Ca2+-activated Cl− channel TMEM16A. Blockade of TMEM16A
is likely to take part in the inhibition of cell proliferation and cancer by niclosamide [15,16,40]. The
present paper identifies a link between CK2 and TMEM16A, as CK2 supports membrane expression
of TMEM16A. Both silmitasertib and niclosamide inhibited proliferation of head and neck cancer
cells. Importantly, simultaneous application of both drugs strongly augmented their antiproliferative
effects. The data suggest a combined treatment by silmitasertib and niclosamide to strongly augment
anti-cancer potency of the individual drugs [40].
2. Material and Methods
2.1. Cell Culture
Cystic fibrosis bronchial epithelial cell lines (CFBE) were grown in minimum essential medium
(MEM) supplemented with 2 mM glutamine. CFBE stably overexpressing 3HA-TMEM16A-eGFP
were cultured in MEM supplemented with 2 mM glutamine, 2.5 µg/mL puromycin and 400 µg/mL
G418. Cal33 and BHY cells, derived from head and neck carcinoma, were grown in DMEM without
antibiotics, as described earlier [16]. All media were supplemented with 10% heat-inactivated fetal calf
serum. All cells were cultured at 37 ◦C in a humidified atmosphere of 5% (v/v) CO2.
2.2. RT-PCR, siRNAs
Semi-quantitative RT-PCR was performed to detect the expression of TMEM16A and CK2 in
CFBE and Cal33 cells. Total RNA was isolated using NucleoSpin RNA II columns (Macherey-Nagel,
Düren, Germany). Total RNA (1 µg/50 µL reaction) was reverse-transcribed using random primers
(Promega, Mannheim, Germany) and Reverse Transcriptase RNase H Minus (Promega, Mannheim,
Germany). Each RT-PCR reaction contained sense and antisense primers for the respective gene (0.5µM)
or for GAPDH (0.5 µM), 0.5 µL cDNA and GoTaq Polymerase (Promega, Mannheim, Germany). After
2 min at 95 ◦C, cDNA was amplified during 30 cycles for 30 s at 95 ◦C, 30 s at 57 ◦C and 1 min at 72 ◦C.
PCR products were visualized by loading on peqGREEN (Peqlab, VWR, Germany) containing agarose
gels and analyzed using Meta Morph Version 6.2 (Molecular Devices, USA). The siRNAs—Silencer™
Select Negative Control siNEG1 (s813), siTMEM16A (HSS182856) and siCSNK2A2 (CK2α’, s3640) were
purchased from ThermoFisher.
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2.3. Patch Clamping
Cells grown on glass-coated cover slips were mounted on the stage of an inverted microscope
(Zeiss, Munich, Germany) and kept at 37 ◦C. Patch pipettes were filled with a cytosolic-like solution
containing (mM) KCl 30, K-gluconate 95, NaH2PO4 1.2, Na2HPO4 4.8, EGTA 1, Ca-gluconate 0.758,
MgCl2 1.03, D-glucose 5, ATP 3, pH 7.2. Patch-clamp experiments were performed in the fast
whole-cell configuration. The bath was perfused continuously with Ringer solution (mM): NaCl 145,
KH2PO4 0.4, K2HPO4 1.6, D-glucose 5, MgCl2 1, Ca-gluconate 1.3, pH 7.4, containing 50 nM TRAM34
(Abcam, ab141885) at a rate of 8 mL/min. Patch pipettes had an input resistance of 2–4 MΩ and whole
cell currents were corrected for serial resistance. Currents were recorded using a patch clamp amplifier
(EPC 7, List Medical Electronics, Darmstadt, Germany), the LIH1600 interface and PULSE software
(HEKA, Lambrecht, Germany) as well as Chart software (AD Instruments, Spechbach, Germany).
In regular intervals, membrane voltage (Vc) was clamped in steps of 20 mV, from −100 to +100 mV
from a holding voltage of −100 mV. Current density was calculated by dividing whole-cell currents by
cell capacitance.
2.4. Western Blotting
Protein was isolated from CFBE and Cal33 cells using a sample buffer containing 50 mM Tris-HCl,
150 mM NaCl, 50 mM Tris, 100 mM dithiothreitol, 1% Nonidet P-40, 0.5% deoxycholate sodium
and 1% protease inhibitor mixture (Sigma, Taufkirchen, Germany). Samples were separated by
7% SDS-PAGE and transferred to nitrocellulose membranes (GE Healthcare, Munich, Germany).
Membranes were blocked with 5% NFM/TBST or 5% NFM/PBST at room temperature for 1 h and
incubated overnight at 4 ◦C with rabbit monoclonal anti-DOG1 antibody (SP31, Novus, Braunschweig,
Germany; 1:500, 1% NFM/TBST) and mouse monoclonal anti-Calnexin antibody (BD Biosciences;
1:5000, 5% NFM/PBST). The mouse anti-CK2α’ antibody (sc-514403, SantaCruz, USA) was used at
1:500 dilution. Subsequently, the membranes were incubated with HRP-conjugated goat anti-mouse or
anti-rabbit, or donkey anti-goat IgG at RT for 2 h. Immunoreactive signals were visualized using a
super-signal chemiluminescence substrate detection kit (Pierce Biotechonology, Rockford, IL, USA).
2.5. Immunocytochemistry
Cells were grown on glass coverslips and fixed with methanol and acetone (4:1) for 10 min at
−20 ◦C. After washing 3 times with PBS supplemented with CaCl2 (0.7 mM) and MgCl2 (1.1 mM),
cells were blocked with 3% bovine serum albumin (BSA) in PBS for 30 min at room temperature (RT),
and incubated with anti-DOG1 primary antibody (1:200) in 1% BSA overnight at 4 ◦C. Binding of the
primary antibody was visualized by incubation with a secondary antibody conjugated with Alexa 488
(1:500) in 1% BSA for 1 h at RT (Life Technologies, A-21206). Nuclei were stained with Hoechst 33342
(0.1 µg/mL PBS, Aplichem, Darmstadt, Germany). Cells were mounted on glass slides with mounting
medium (DAKO Cytomation, Hamburg, Germany) and examined with an Axiovert 200 microscope
equipped with ApoTome and AxioVision (Zeiss, Germany). Cellular distribution of endogenous
TMEM16A was analyzed in CFBE or Cal33 cells in the presence or absence of CK2α’. Membrane and
cytosolic expression were quantified in each cell by analyzing fluorescence intensities in the regions of
interest (ROI) using the software ImageJ. Membrane regions were validated using high-resolution DIC
image, that allowed us to clearly identify the plasma membrane of each cell.
2.6. Measurement of [Ca2+]i
Measurement of the global cytosolic Ca2+ changes were performed as described recently [41]. In
brief, cells were loaded with 5 µM Fura-2, AM (Molecular Probes) in OptiMEM (Invitogen) with 0.02%
pluronic (Molecular Probes) for 1 h at RT and 30 min at 37 ◦C. Fura-2 was excited at 340/380 nm, and
the emission was recorded between 470 and 550 nm using a CCD-camera (CoolSnap HQ, Visitron
Systems, Germany). Control of experiment, imaging acquisition and data analysis were done with the
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software package Meta-Fluor (Universal imaging, USA). [Ca2+]i was calculated from the 340/380 nm
fluorescence ratio after background subtraction. The formula used to calculate [Ca2+]i was [Ca2+]i =
Kd × (R − Rmin)/(Rmax − R) × (Sf2/Sb2), where R is the observed fluorescence ratio. The values Rmax and
Rmin (maximum and minimum ratios) and the constant Sf2/Sb2 (fluorescence of free and Ca2+-bound
Fura-2 at 380 nm) were calculated using 1 µmol/liter ionomycin (Calbiochem), 5 µmol/liter nigericin,
10 µmol/liter monensin (Sigma) and 5 mmol/liter EGTA to equilibrate intracellular and extracellular
Ca2+ in intact Fura-2-loaded cells. The dissociation constant for the Fura-2•Ca2+ complex was taken as
224 nmol/L.
2.7. Proliferation and Cell Death Assay
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT, M2128, Sigma-Aldrich,
Taufkirchen, Germany), was dissolved in PBS to a final concentration of 5 mg/mL. The solution was
filtered and stored at −20 ◦C, protected from the light. To determine proliferation, Cal33 cells or
BHY cells (1.5 × 103 cells) were seeded into 96-well plates and allowed to adhere overnight. The
next day, cells were transfected with siRNAs (siTMEM16A, siCSNK2A2 or “scrambled” non-targeting
siRNA) and/or treated with drugs (20 µM CX-4945, 0.5 µM niclosamide, 1 µM Ani9, 10 µM Eact or
DMSO). Every 2 days, cells were again transfected and/or the medium with drugs was replaced, and
experiments were performed. The medium was removed and 10 µL of MTT were added per well,
together with 90 µL of new medium. MTT produces a yellowish solution that is converted to dark blue
water-insoluble MTT formazan by mitochondrial dehydrogenases of living cells, therefore allowing
the quantification of the living cells per well. After 2 h of incubation at 37 ◦C, the blue crystals were
solubilized with DMSO and the intensity was measured colorimetrically at 570 nM using the plate
reader NOVOstar (BMG Labtech, Offenburg, Germany).
2.8. Materials and Statistical Analysis
The CK2 inhibitors CX-4945 (silmitasertib) and TBB (4,5,6,7-Tetrabromobenzotriazole) were
purchased from Cayman Chemicals and Sigma, respectively. Niclosamide was from Sigma (Germany).
Data are reported as means ± SEM. Student’s t-test (for paired or unpaired samples as appropriate) or
ANOVA were used for statistical analysis. A value of p < 0.05 was accepted as a significant difference.
3. Results
3.1. High-Throughput Assay Identifies CK2 as a Regulator of TMEM16A
A microscopy-based assay has been performed to identify novel regulators of the Ca2+-activated
Cl− channel TMEM16A [42]. siRNA screening for interactors of TMEM16A was performed in CFBE
airway epithelia cells overexpressing double-tagged TMEM16A. CFBE cells were chosen because we
intended to identify proteins that could be targeted in order to improve TMEM16A function, and
thus Ca2+-dependent Cl− secretion in cystic fibrosis airway epithelial cells [43]. We identified CK2
as a positive regulator of TMEM16A. Because TMEM16A is particularly known to be upregulated in
head and neck squamous cell carcinomas (HNSCC), where CK2 also has a pro-cancerous role [43],
we examined the hypothesis that CK2 promotes proliferation of the HNSCC cell lines Cal33 and
BHY through activation of TMEM16A, which would have consequences for the treatment of HNSCC.
siRNA-knockdown of the broadly expressed casein kinase 2 subunit CK2α’ was found to downregulate
membrane expression of overexpressed TMEM16A containing a C-terminal green fluorescence protein
(GFP) and an extracellular (human influenza hemagglutinin) HA tag (Figure 1A–C). Membrane
expression was detected using an extracellular HA tag and binding of a fluorescent antibody to
the extracellular HA tag. We examined whether endogenously expressed TMEM16A is equally
regulated by CK2 and used CFBE cells that express only endogenous TMEM16A. Indeed, plasma
membrane expression of endogenous TMEM16A was significantly inhibited upon knockdown of
CK2α’ (Figure 1D,E). This effect of knockdown of CK2α’ was specific in as much as membrane
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expression of the common housekeeper ATPase Na+/K+-ATPase was not affected by the knockdown
(Supplementary Figure S1).Cells 2020, 9, x FOR PEER REVIEW 5 of 16 
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Expression of double-tagged (eGFP and extracellular HA-tag) TMEM16A in CFBE airway epithelial 
cells. Membrane localized TMEM16A (Alexa647 positivity) was detected by an extracellular anti-HA-
Alexa647-conjugated antibody. (B,C) RT-PCR and densitometric analysis indicating successful 
knockdown of CK2α’, #significant inhibition (unpaired t-test; p = 0.01). (D,E) Immunocytochemistry 
of TMEM16A expressed endogenously in CFBE cells. Membrane expression was reduced by 
knockdown of CK2α’, #significant inhibition (unpaired t-test; p = 0.000000002). Mean ± SEM. In 
parentheses are numbers of experiments. 
3.2. Knockdown or Inhibition of CK2 Inhibits Activation of TMEM16A.  
TMEM16A is a Ca2+-activated Cl- channel that is activated through stimulation of G-protein 
coupled receptors (GPRCs) that couple to phospholipase C, such as ATP-activated purinergic 
receptors. Stimulation of CFBE cells with extracellular ATP does increase intracellular Ca2+, which in 
turn will activate TMEM16A [42,44]. As shown in Figure 2, ATP activated TMEM16A whole cell 
currents in CFBE cells. Activation was strongly suppressed by preincubation of the cells for 30 min 
Figure 1. CK2 controls membrane expression of TMEM16A in CFBE airway epithelial cells.
(A) Expression of double-tag (eGFP and extr cellul r HA-tag) TMEM16A in CFBE airway
epithelial cells. embrane localized TMEM16A (Alexa647 positivity) was detected by an extracellular
anti-HA-Alexa647-conjugated antibody. (B,C) RT-PCR and densitometric analysis indicating successful
knockdown of CK2α’, #significant inhibition (unpaired t-test; p = 0.01). (D,E) Immunocytochemistry of
TMEM16A expressed endogenously in CFBE cells. Membrane expression was reduced by k ockdown
of CK2α’, #sig ificant i hibition (unpaired t-test; p = 0.000000002). Mean ± SEM. In parentheses are
numbers of experiments.
3.2. Knockdown or Inhibit on of CK2 Inhibits Activation of TMEM16A
TMEM16A is a Ca2+-activated Cl− channel that is activated through stimulation of G-protein
coupled receptors (GPRCs) that couple to phosphol pase C, such as ATP-activated purinergic receptors.
Stimulation of CFBE cells with extracellular ATP does increase intracellular Ca2+, which in turn will
activate TMEM16A [42,44]. As shown in Figure 2, ATP activated TMEM16A whole cell currents in
CFBE cells. Activation was strongly suppressed by preincubation of the cells for 30 min with the CK2
inhibitor TBB (Figure 2A). The summary of these experiments is shown in Figure 2B as current/voltage
relationships of ion currents activated in control cells (left) and in TBB-treated cells (right). We also
found that the CK2 inhibitor CX4945 suppressed ATP-induced whole cell currents even more potently
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than TBB (Figure 2C,D). In contrast, acute application of CX4945 to pre-activated TMEM16A did
not clearly inhibit whole cell currents. Finally, knockdown of CK2α’ (siCK2α’) strongly attenuated
TMEM16A currents stimulated by ATP (Figure 2E,F). Similar to knockdown of CK2α’ (Figure 1D),
CX4945 also inhibited membrane expression of TMEM16A (Figure 2F,G).
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Figure 2. Inhibitors of CK2 inhibit TMEM16A i FBE airway epithelial cells. (A–F) Whole cell current
overlay recorded in patch clamp experiments and current/voltage relationships. ATP (100 µM) activated
TMEM16A whole cell Cl− currents that were strongly inhibited by the CK2-inhibitors TBB (10 µM;
#significant inhibition, unpaired t-test; p = 0.01, (A,B)) and CX4945 (20 µM; #significant inhibition,
unpaired t-test; p = 0.02; (C,D)), and siRNA-knockdown of CK2α’ (#significant inhibition, unpaired
t-test; p = 0.0001; (E,F)). (G,H) Plasma membrane (PM) expression of endogenous TMEM16A in CFBE
cells and inhibition of PM expression by the CK2-inhibitor CX4945 (#significant inhibition, unpaired
t-test; p = 0.000000000007). Mean± SEM #significant inhibition (p < 0.05; unpaired t-test). In parentheses
are numbers of experiments.
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3.3. CK2 Regulates Membrane Expression of TMEM16A in Cal33 Head and Neck Cancer Cells
TMEM16A is strongly expressed in head and neck cancer cells. The coding sequence of TMEM16A
is located in the tumor-associated amplicon 11q13. High expression levels for TMEM16A correlate
with poor survival of patients with head and neck cancers [16]. Our previous studies demonstrated
the proliferative effect of TMEM16A in different head and neck cancer cell lines such as Cal27, Cal33
and BHY, as well as growth of soft tissue cancer in nude mice [15,16,40]. We therefore analyzed
CK2-dependent regulation of TMEM16A-expression in Cal33 cells using siRNA for CK2α’, which
potently suppressed CK2α’ mRNA as well as protein (Figure 3A–C). However, siRNA-knockdown
of CK2α’ did not affect total expression of TMEM16A, as shown by Western blotting (Figure 3D). In
contrast and similar to CFBE cells, knockdown of CK2α’ clearly reduced plasma membrane expression
of TMEM16A in Cal33 cells (Figure 3E,F). Accordingly, TMEM16A currents activated by ATP were also
inhibited by knockdown of CK2α’ (Figure 3G). However, attenuation of TMEM16A currents was less
pronounced than in CFBE cells, which is due to excessive levels of TMEM16A-expression in Cal33
cells [16]. Cells 2020, 9, x FOR PEER REVIEW 8 of 16 
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present study with Cal33 cells (Figure 4A). siRNA-knockdown of CK2α’ inhibited cell proliferation 
equally well. Notably, combined knockdown of both TMEM16A and CK2α’ had a more pronounced 
inhibitory effect on cell proliferation (Figure 4A). It suggests that CK2 and TMEM16A control cell 
proliferation in part by independent mechanisms. This was also found when CK2 was inhibited by 
CX4945 instead of siRNA-knockdown. CX5945 alone inhibited proliferation similar to siRNA-CK2α’, 
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Figure 3. Role of CK2 for plasma membrane expression of TMEM16A in Cal33 head and neck cancer
cells. (A,B) RT-PCR and densitometric analysis indicating successful knockdown of CK2α’ by siRNA
for CK2α’ in Cal33 head and neck cancer cells (#si ificant inhibition, unpaired t-test; p = 0.01).
Knockdown f CK2α’ did not inhibit transcription of TMEM16A. (C,D) West rn blot analysis indicating
successful knockdown of CK2α’ but unaffected expression of TMEM16A. (E,F) Plasma membrane (PM)
expression of TMEM16A expressed endogenously in Cal33 cells and inhibition of PM expression by
knockdown of CK2α’ (#significant inhibition, unpaired t-test; p = 0.00000002). (G) Current/voltage
relationships of ATP-activate TMEM16A whole cells currents, indica ing inhibition of T EM16A by
knockdown of CK2α’ (#significant inhibition, unpaired t-test; p = 0.01). Mean ± SEM. In parentheses
are numbers of experiments.
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3.4. Inhibition of CK2 and TMEM16A Inhibits Cell Proliferation
Knockdown of TMEM16A attenuates cell proliferation [16], and this was also observed in the
present study with Cal33 cells (Figure 4A). siRNA-knockdown of CK2α’ inhibited cell proliferation
equally well. Notably, combined knockdown of both TMEM16A and CK2α’ had a more pronounced
inhibitory effect on cell proliferation (Figure 4A). It suggests that CK2 and TMEM16A control cell
proliferation in part by independent mechanisms. This was also found when CK2 was inhibited by
CX4945 instead of siRNA-knockdown. CX5945 alone inhibited proliferation similar to siRNA-CK2α’,
but CX4945 + siRNA-TMEM16A abolished proliferation completely (Figure 4B).
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Figure 4. Inhibition of proliferation by knockdown of CK2α’ and TMEM16A. (A) Cell proliferation
assessed in MTT assays and shown as absorbance. B th siRNA-knockdown of CK2α’ and TMEM16A
inhibited cell proliferation (#sig ific nt inhibition, unpaired t-tests; p = 0.0001). Simultaneous
knockdown of CK2α’ nd TMEM16A had a more pronounce inhibitory effect on cell proliferation
(#significa t inhibition, unpaired t-test; p = 0.0015). (B) Inhibition of cell proliferati n by the
CK2-inhibitor CX4945 (20 µM) and additional inhibitory effect of TMEM16A-knockdown (#significant
ion, unpaired t-test; p = 0.0001). Mean ± SEM. In parentheses are numbers of experime ts.
As outlined above, niclosamide is a potent inhibitor of TMEM16A and an anticancer drug. It also
inhibited proliferation of Cal33 cells in th present study (Figure 5A). Again, the ombination of
niclosamide together with CX4945 complet ly inhibited cell prolif ration (Figure 5A). We performed
similar studies in BHY cells, another head and neck cancer cell line [16], i order to validate the results
obtained in Cal33 cells. Application of only CX4945 or niclosamide i hibited cell proliferation by
a out 50%. In contrast, simultane us application of CX4945 and niclosamide essentially abolished
pr liferation (Figu e 5B). Interestingly, the ctivator of TMEM16A, Eact [45], further augment
li i of BHY cells (Figure 5B).
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Because intracellular Ca2+ is a major regulator of cell proliferation, we examined if inhibition of 
TMEM16A by niclosamide exerts similar effects on intracellular Ca2+ signaling in Cal33 cells. 
Niclosamide did not change basal intracellular Ca2+ concentrations but strongly attenuated Ca2+ rise, 
induced by 10 and 100 µM ATP, respectively (Figure 6). It is notable that the CK2-inhibitor CX4945 
also strongly reduced intracellular Ca2+ levels. This previously unrecognized effect of CX4945 on 
intracellular Ca2+ is likely to contribute to its antiproliferative/anticancer effects. Simultaneous 
inhibition of TMEM16A and CK2 did not further increase the inhibitory effect on [Ca2+]i. Taken 
together, blocking CK2 and TMEM16A inhibits cell proliferation, partially by overlapping 
mechanisms. Because inhibition of both pathways significantly augments inhibition of cell 
proliferation, it may be considered to use CX4945 and niclosamide simultaneously in patients with 
cancer. 
Figure 5. Blockers of CK2 and TMEM16A inhibit proliferation of Cal33 and BHY head and neck
cancer cells. (A) Blocking CK2 by CX4945 (20 µM) and blocking TMEM16A by niclosamide (0.5 µM)
inhibited proliferation of Cal33 cells. Simultaneous application of both blockers had an additive
effect (#significant inhibition, unpaired t-tests; p = 0.0001). (B) Enhanced cell proliferation of BHY
cells induced by the TMEM16A-activator, Eact. Blocking CK2 by CX4945 (20 µM) and blocking
TMEM16A by niclosamide (0.5 µM) inhibited proliferation of BHY cells. Simultaneous application of
both blockers had an additive effect (#significant inhibition, unpaired t-tests; p = 0.000015). Mean ±
SEM. In parentheses are numbers of experiments.
3.5. Inhibition of TMEM16A and Inhibition of CK2 Attenuates Receptor-Mediated Increase in the Intracellular
Ca2+ Concentration
TMEM16A has a pronounced impact on intracellular Ca2+ ([Ca2+]i) signaling, as reported earlier,
which is explained by its interaction with the endoplasmic reticulum (ER) inositolphosphate receptor
IP3R and possibly by the impact of TMEM16A-mediated Cl− transport on Ca2+ signaling [40,46,47].
Because intracellular Ca2+ is a major regulator of cell proliferation, we examined if inhibition
of TMEM16A by niclosamide exerts similar effects on intracellular Ca2+ signaling in Cal33 cells.
Niclosamide did not change basal intracellular Ca2+ concentrations but strongly attenuated Ca2+
rise, induced by 10 and 100 µM ATP, respectively (Figure 6). It is notable that the CK2-inhibitor
CX4945 also strongly reduced intracellular Ca2+ levels. This previously unrecognized effect of CX4945
on intracellular Ca2+ is likely to contribute to its antiproliferative/anticancer effects. Simultaneous
inhibition of TMEM16A and CK2 did not further increase the inhibitory effect on [Ca2+]i. Taken
together, blocking CK2 and TMEM16A inhibits cell proliferation, partially by overlapping mechanisms.
Because inhibition of both pathways significantly augments inhibition of cell proliferation, it may be
considered to use CX4945 and niclosamide simultaneously in patients with cancer.
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4. Discussion
CK2 and TMEM16A Regulate Cell Proliferation
In the present study, we have shown that the ubiquitous and constitutively active kinase CK2
controls membrane expression of the Ca2+-activ ted Cl− channel, TMEM16A, in vitro. High-throughput
s reening was performed by stably expressing a TMEM16A onstruct (3HA-TMEM16A-eGFP) in
CFBE cells, that contains a h magglutinin t g (YPYDVPDYA) inserted in triplicate (3HA) between
His396 a d Asn397, i.e., in the first extracellular loop of TMEM16A. Th s ex racellular HA-tag, if
pr sent, can be immuno-detected in non-perme bi ized cells, as the antibody binds only to the plasma
membra e-localiz d TMEM16A. Images were acquired using an automated w defield epifluorescence
microscope. It means th t c lls were illuminated from above and the whole specimen was expos d to
the light source, explaining this type of membrane staining [42]. The results identify TMEM16A as
anoth r i n channel that is regulated by CK2.
arlier studies d monstrated that the cystic fibrosis transmembrane conductance regulator (CFTR)
requires CK2 to be fully active [48–51]. We and others also demonstrated th t CK2 positively regulates
the epithelial Na+ channel, ENaC, which is important to cont ol renal Na+ excretion [52,53]. For both
CFTR nd ENaC, consensus sides for CK2-dependent phosphorylation have been found. We searched
for puta ive CK2 phosphorylation sites in human TMEM16A (abcd isof rm) using PROSCAN/PROSITE
databases, and identified 10 putative CK2 phosphorylation sites. Two stronger consensus CK2 sides
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were located at the N-terminus and one was located at the C-terminus of TMEM16A. The N-terminus is
relevant for membrane trafficking. Its elimination abolished expression. Truncation of the C-terminus
reduced ATP-activated whole cell currents in our previous report [54,55]. This could suggest a role of
CK2 phosphorylation for activation of TMEM16A. However, it is currently unclear whether these sides
are truly phosphorylated by CK2. For example, a serine is located at position 42 within the N-terminus
and may possibly affect membrane targeting when phosphorylated. S42 phosphorylation could
also change the interaction of TMEM16A with accessory proteins, such as the ezrin–radixin–moesin
network [56].
A role of CK2 has been found for several other ion channels and transporters [51,57,58]. As for
TMEM16A, also for CFTR and ENaC, CK2 was shown to support their intracellular processing and
trafficking to the plasma membrane [52,59]. In this context, it is noteworthy that CK2 phosphorylates
Sec31 and regulates ER-To-Golgi trafficking [60]. Also, peripheral steps of membrane fusion, exocytosis
and insertion of proteins into the plasma membrane via the synaptosomal-associated protein receptor
(SNARE) machinery is controlled by CK2 [61]. Transcription of TMEM16A is under the control of the
transcription factor signal transducer and activator of transcription 6 (STAT6), while CK2 is known to
affect STAT6 activity [62,63]. However, we did not find evidence for reduced expression of TMEM16A
by inhibition of CK2. Taken together, inhibition of CK2 is likely to inhibit TMEM16A activity, in
part by inhibition of plasma membrane expression and probably by inhibition of intracellular Ca2+
signaling [54].
An essential result of the present study is that co-application of niclosamide enhanced the
anti-proliferative effect of CX4945 remarkably (Figure 5), but at the same time, lowered the
cytotoxic (cell death) effect exerted by CX4945 (Supplementary Figure S2). The inhibitory effect
of niclosamide on cell proliferation was validated by Ani9, another more specific inhibitor of TMEM16A
(Supplementary Figure S3). Therefore, combined inhibition of CK2 and TMEM16A by CX4945 and
niclosamide respectively, would maybe reduce the concentration of CX4945 required in a cancer
patient. While our present data only demonstrate inhibitory effects of CX4945 in vitro, our previous
experiments also demonstrated the role of TMEM16A for cancer growth in vivo [15,16]. Although
CX4945 was used at µM concentrations in the present in vitro study, additional experiments show that
it also inhibits proliferation at nanomolar concentrations (Supplementary Figure S4). Taken together,
we may speculate that co-application of niclosamide together with CX4945 could allow for further
reduction of the CX4945 dosage in vivo, to maybe reach effective picomolar concentrations that would
come close to the concentrations used in monoclonal antibody therapy. This could reduce unwanted
side effects of an anti-cancer therapy by inhibitors of CK2 [64].
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/9/5/1138/s1.
Figure S1: CK2 does not affect membrane expression of Na+/K+-ATPase. Supplementary Figure S2: CX4945, but
not niclosamide, induces cell death. Supplementary Figure S3: The TMEM16A inhibitor Ani9 inhibits proliferation.
Supplementary Figure S4: Inhibition of cell proliferation by different concentrations of CX4945.
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Abbreviations
ATP adenosine triphosphate
BSA bovine serum albumin
CaCC calcium (Ca2+)-activated Cl– channel
CFBE cystic fibrosis bronchial epithelial (cells)




GPCR G-protein coupled receptor
HA hemagglutinin
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyl-2H-tetrazolium bromide
PBS phosphate buffered saline
PM plasma membrane
RT room temperature
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